MAPK10-AS1

Across TCGA pan-cancer cohorts, MAPK10-AS1 RNA is linked to patient survival in 20 of 34 cancer types, making it the most broadly survival-associated MAPK10-AS1 data layer.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher MAPK10-AS1 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MAPK10-AS1 expression acts as an unfavorable survival marker, although some lineages such as DLBC and LGG show a favorable association.

CHOL, THCA, and LIHC are the cancer types where MAPK10-AS1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Tertile	II,III,IV	0.019	0.765	.001	54	view →
THCA	OS	Tertile	All	0.956	1.000	.001	36	view →
LIHC	DFS	Tertile	All	0.368	0.560	.003	36	view →
SKCM	DFS	Quartile	IV	0.060	0.536	.007	28	view →
MESO	DFS	Tertile	II,III,IV	0.213	0.582	.005	24	view →
DLBC	DFS	Median	II,III,IV	1.000	0.667	.005	20	view →
ACC	OS	Tertile	III,IV	0.550	0.863	.014	17	view →
HNSC	OS	Tertile	III,IV	0.368	0.600	.020	14	view →
LUSC	OS	Median	IV	0.255	0.851	.021	12	view →
KIRC	DFS	Tertile	All	0.499	0.703	.007	12	view →
KIRP	DFS	Tertile	All	0.801	0.919	.009	11	view →
LGG	OS	Tertile	All	0.603	0.396	.004	11	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 20 lineages.

MAPK10-AS1–CHOL (OS)

Open the CHOL breakdown →